Menace or medicine? Anthropological perspectives on the self-administration of high potency cannabis in the UK Anna Waldstein Drugs and Alcohol Today • Volume 10 Issue 3 • September 2010 Abstract Domestically produced, high potency cannabis (often referred to as ‘skunk’ in the mainstream UK media) has become increasingly widespread in the UK. This paper considers whether the trend reflects an increased awareness of and desire for medical marijuana. Determining whether cannabis is a drug or a medicine depends on its objective physiological effects – which may vary from one individual to another – as well as how and why those effects are experienced. The [...]
Lire la suiteCannabinol and Neuropathic Pain P.W. Brownjohn and J.C. Ashton Neuropathic Pain, 2012, chap. 4, 79-102 1. Introduction Cannabinoids are drugs that are either derived from cannabis or that induce similar behavioural and physiological effects to cannabis. They fall into three classes: those that are produced by plants of the Cannabis genus, termed phytocannabinoids (plant cannabinoids); those that are produced within the body, termed endocannabinoids (endogenous cannabinoids); and those that are produced synthetically to mimic the pharmacology of naturally occurring cannabinoids. Cannabinoids stand in relation to cannabis as opioids such as codeine, pethidine, fentanyl, and methadone stand in relation to opium. While opium and opioids [...]
Lire la suiteCannabidiol : Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley, and Daniel Friedman Epilepsia, 2014, 55, 6, 791–802, doi: 10.1111/epi.12631 SUMMARY To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders.Wesummarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data [...]
Lire la suiteCannabinoïds and cancer: causation, remediation, and palliation Wayne Hall, MacDonald Christie, David Currow Lancet Oncology, 2005, 6, 35–42 http://oncology.thelancet.com This review discusses three different associations between cannabinoids and cancer. First, it assesses evidence that smoking of cannabis preparations may cause cancers of the aerodigestive and respiratory system. There have been case reports of upper-respiratory-tract cancers in young adults who smoke cannabis, but evidence from a few epidemiological cohort studies and case-control studies is inconsistent. Second, there is mixed evidence on the effects of THC and other cannabinoids on cancers: in some in vitro and in vivo studies THC and some synthetic cannabinoids have had [...]
Lire la suitePatient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain Patrick Makary, Jayesh R. Parmar, Natalie Mims, Nile M. Khanfar and Robert A. Freeman JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2019 https://doi.org/10.1080/15360288.2019.1598531 ABSTRACT The use of cannabis medications has grown in recent years for the symptomatic relief of chemotherapy-induced nausea/vomiting (CINV) and chronic pain (cancer-related and noncancer-related). As states legalize the use of cannabis, it is important for pharmacists and other health care professionals to beaware of how to counsel patients receiving prescriptions for cannabis medications. The aim of this study was to develop patient counseling guidelines [...]
Lire la suiteProspects for the Use of Cannabinoids in Oncology and Palliative Care Practice : A Review of the Evidence Tomasz Dzierżanowski Cancers, 2019, 11, 129 doi:10.3390/cancers11020129 Abstract : There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was [...]
Lire la suiteDeconstructing Ecstasy : The Politics Of MDMA Research Charles S. Grob Addiction Research, 2000, 8, 6, 549-588 http://dx.doi.org/10.3109/16066350008998989 What is Ecstasy? Defined by the New Webster’s Dictionary as a state of intense overpowering emotion, a condition of exultation or mental rapture induced by beauty, music, artistic creation or the contemplation of the divine, ecstasy derives etymologically from the ancient Greek ekstasis, which means flight of the soul from the body. The anthropologist, Mircea Eliade, who explored the roots of religious experience in his book Shamanism: Archaic Techniques of Ecstasy, has described the function of this intense state of mind among aboriginal peoples. Select individuals are [...]
Lire la suiteREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics R. L. Carhart-Harris and K. J. Friston Pharmacological Reviews, 2019, 71, 316–344 https://doi.org/10.1124/pr.118.017160 Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteA Review of Cannabis in Chronic Kidney Disease Symptom Management Claudia Ho, Dan Martinusen, and Clifford Lo2,4,5 Canadian Journal of Kidney Health and Disease, 2019, Volume 6, 1–14 DOI: 10.1177/2054358119828391 journals.sagepub.com/home/cjk Abstract Purpose of Review : Physical and psychological symptom burden in patients with advanced chronic kidney disease (CKD) is significantly debilitating; yet, it is often inadequately treated. Legalization of cannabis in Canada may attract increasing interest from patients for its medical use in refractory symptom management, but its indications and long-term adverse health impacts are poorly established, creating a challenge for clinicians to support its use. In this review, we summarize key clinical studies and [...]
Lire la suiteA burning problem: cannabis lessons learned from Colorado Jamie E. Parnes, Adrian J. Bravo, Bradley T. Conner and Matthew R. Pearson ADDICTION RESEARCH & THEORY, 2018, VOL. 26, NO. 1, 3–10 http://dx.doi.org/10.1080/16066359.2017.1315410 ABSTRACT With recent increases in cannabis’ popularity, including being legalized in several states, new issues have emerged related to use. Increases in the number of users, new products, and home growing all present distinct concerns. In the present review, we explored various cannabis-related concerns (i.e. use, acquiring, growing, and public health/policy) that have arisen in Colorado in order to provide information on emerging issues and future directions to mitigate negative outcomes that could [...]
Lire la suite